X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (43007) 43007
Book Review (9374) 9374
Newspaper Article (6755) 6755
Publication (4081) 4081
Trade Publication Article (367) 367
Book Chapter (201) 201
Newsletter (195) 195
Magazine Article (173) 173
Conference Proceeding (135) 135
Book / eBook (62) 62
Web Resource (60) 60
Transcript (50) 50
Dissertation (20) 20
Government Document (15) 15
Paper (6) 6
Reference (3) 3
Data Set (2) 2
Report (2) 2
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (37983) 37983
humans (34857) 34857
male (21449) 21449
oncology (19658) 19658
female (19388) 19388
middle aged (16456) 16456
aged (13906) 13906
adult (13698) 13698
cancer (10655) 10655
drug dosages (10487) 10487
treatment outcome (9715) 9715
clinical trials (7904) 7904
dose-response relationship, drug (7815) 7815
care and treatment (7306) 7306
chemotherapy (7232) 7232
pharmacology & pharmacy (7005) 7005
radiotherapy (6838) 6838
patients (6121) 6121
animals (5985) 5985
radiology, nuclear medicine & medical imaging (5964) 5964
research (5737) 5737
antineoplastic combined chemotherapy protocols - therapeutic use (5122) 5122
tumors (5024) 5024
aged, 80 and over (4941) 4941
drug therapy (4884) 4884
radiotherapy dosage (4764) 4764
therapy (4557) 4557
medicine & public health (4455) 4455
dosage and administration (4395) 4395
drug administration schedule (4138) 4138
analysis (3889) 3889
hematology, oncology and palliative medicine (3699) 3699
hematology (3553) 3553
health aspects (3489) 3489
toxicity (3480) 3480
adolescent (3444) 3444
cancer therapies (3429) 3429
pharmacokinetics (3346) 3346
studies (3315) 3315
antineoplastic agents - administration & dosage (3080) 3080
radiation-therapy (3017) 3017
antineoplastic combined chemotherapy protocols - adverse effects (2992) 2992
trial (2958) 2958
retrospective studies (2873) 2873
metastasis (2870) 2870
medical research (2829) 2829
prostate cancer (2755) 2755
abridged index medicus (2742) 2742
neoplasms - drug therapy (2726) 2726
young adult (2701) 2701
maximum tolerated dose (2693) 2693
follow-up studies (2632) 2632
time factors (2622) 2622
article (2620) 2620
neoplasm staging (2620) 2620
antineoplastic agents - therapeutic use (2613) 2613
dose-escalation (2580) 2580
carcinoma (2525) 2525
pharmacology/toxicology (2441) 2441
prostatic neoplasms - radiotherapy (2435) 2435
pharmaceutical industry (2384) 2384
radiation therapy (2297) 2297
radiation (2295) 2295
combined modality therapy (2269) 2269
risk factors (2242) 2242
disease-free survival (2229) 2229
safety (2180) 2180
prognosis (2161) 2161
survival (2138) 2138
double-blind (2136) 2136
prospective studies (2126) 2126
medicine (2099) 2099
mice (2087) 2087
efficacy (2075) 2075
administration, oral (2058) 2058
antineoplastic agents - adverse effects (2049) 2049
child (1988) 1988
double-blind method (1974) 1974
antineoplastic combined chemotherapy protocols - administration & dosage (1971) 1971
surgery (1956) 1956
radiology (1946) 1946
survival rate (1895) 1895
pharmacology (1884) 1884
immunotherapy (1794) 1794
lung cancer (1782) 1782
clinical trials as topic (1775) 1775
survival analysis (1759) 1759
leukemia (1745) 1745
usage (1739) 1739
breast cancer (1726) 1726
immunology (1718) 1718
neurosciences (1717) 1717
clinical neurology (1713) 1713
dose fractionation (1700) 1700
drug therapy, combination (1695) 1695
complications and side effects (1685) 1685
antineoplastic agents (1681) 1681
radiology and nuclear medicine (1676) 1676
rats (1650) 1650
cisplatin (1577) 1577
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (37) 37
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (7) 7
Collection Dvlpm't (Acquisitions) - Closed Orders (5) 5
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
Online Resources - Online (3) 3
Gerstein Science - Missing (1) 1
Gerstein Science - Reference (1) 1
Humber River Regional Hospital - Finch Stacks (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - General (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (50421) 50421
French (174) 174
German (141) 141
Japanese (31) 31
Spanish (21) 21
Hungarian (14) 14
Chinese (11) 11
Polish (8) 8
Russian (7) 7
Czech (5) 5
Dutch (5) 5
Italian (5) 5
Korean (5) 5
Serbian (4) 4
Norwegian (3) 3
Portuguese (2) 2
Urdu (2) 2
Danish (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Breast, The, ISSN 0960-9776, 2017, Volume 34, pp. 24 - 33
Journal Article
Radiotherapy and Oncology, ISSN 0167-8140, 2014, Volume 111, Issue 1, pp. 81 - 87
Abstract Objective To investigate the effect of radiation dose-escalation on local control in hypoxic versus non-hypoxic hypoxic tumours defined using [18... 
Hematology, Oncology and Palliative Medicine | Single dose irradiation | Squamous cell carcinoma | Dose escalation | Local control | [18F]FMISO positron emission tomography | Human tumour xenografts | Hypoxic volume | OXYGEN-TENSION | RADIATION ONCOLOGY | [F-18]FMISO positron emission tomography | ADVANCED HEAD | NECK-CANCER | TUMOR-CONTROL | POSITRON-EMISSION-TOMOGRAPHY | F-18 FLUOROMISONIDAZOLE | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | F-18-FLUOROMISONIDAZOLE PET | FRACTIONATED-IRRADIATION | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Neoplasm Recurrence, Local - radiotherapy | Cell Hypoxia - radiation effects | Carcinoma, Squamous Cell - metabolism | Carcinoma, Squamous Cell - pathology | Humans | Misonidazole - administration & dosage | Carcinoma, Squamous Cell - diagnostic imaging | Carcinoma, Squamous Cell - radiotherapy | Head and Neck Neoplasms - metabolism | Neoplasm Recurrence, Local - pathology | Squamous Cell Carcinoma of Head and Neck | Radiation-Sensitizing Agents - administration & dosage | Fluorine Radioisotopes - administration & dosage | Neoplasm Recurrence, Local - diagnostic imaging | Female | Neoplasm Recurrence, Local - metabolism | Head and Neck Neoplasms - diagnostic imaging | Misonidazole - analogs & derivatives | Random Allocation | Head and Neck Neoplasms - pathology | Radiopharmaceuticals - administration & dosage | Xenograft Model Antitumor Assays | Head and Neck Neoplasms - radiotherapy | Hypopharyngeal Neoplasms - radiotherapy | Animals | Hypopharyngeal Neoplasms - metabolism | Mice, Nude | Hypopharyngeal Neoplasms - pathology | Radionuclide Imaging | Cell Line, Tumor | Mice | Dose-Response Relationship, Radiation | Hypopharyngeal Neoplasms - diagnostic imaging | Nuclear radiation | Index Medicus
Journal Article
Strahlentherapie und Onkologie, ISSN 0179-7158, 4/2012, Volume 188, Issue 4, pp. 334 - 339
Dose escalations above 60 Gy based on MRI have not led to prognostic benefits in glioblastoma patients yet. With positron emission tomography (PET) using... 
Glioblastom | Medicine & Public Health | Dose escalation | Glioblastoma | Oncology | Dose fractionation | Dosisfraktionierung | Radiotherapy | Dosiseskalation | Strahlentherapie | POSTOPERATIVE RADIOTHERAPY | VOLUME | MULTIFORME | ADJUVANT TEMOZOLOMIDE | TRIAL | AMINO-ACID | STEREOTACTIC RADIOSURGERY | ONCOLOGY | FRACTIONATED RADIOTHERAPY | CONFORMAL RADIOTHERAPY | HIGH-GRADE GLIOMAS | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Prospective Studies | Follow-Up Studies | Radiotherapy Planning, Computer-Assisted - methods | Humans | Middle Aged | Male | Chemoradiotherapy, Adjuvant | Glioblastoma - radiotherapy | Tyrosine - analogs & derivatives | Supratentorial Neoplasms - drug therapy | Tyrosine - therapeutic use | Mental Status Schedule | Adult | Dose Fractionation | Female | Supratentorial Neoplasms - pathology | Radiotherapy, Intensity-Modulated - methods | Supratentorial Neoplasms - mortality | Brain - radiation effects | Combined Modality Therapy | Positron-Emission Tomography - methods | Supratentorial Neoplasms - surgery | Glioblastoma - surgery | Radiation Injuries - etiology | Supratentorial Neoplasms - radiotherapy | Disease-Free Survival | Magnetic Resonance Imaging | Glioblastoma - pathology | Quality of Life | Aged | Glioblastoma - drug therapy | Glioblastoma - mortality | Neurosciences | Nuclear radiation | Radiation | Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2016, Volume 375, Issue 2, pp. 111 - 121
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10088, pp. 2492 - 2502
Summary Background For patients with advanced hepatocellular carcinoma, sorafenib is the only approved drug worldwide, and outcomes remain poor. We aimed to... 
Internal Medicine | CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | IMMUNOTHERAPY | SORAFENIB | BLOCKADE | DOCETAXEL | PD-1 | Drug Administration Schedule | Humans | Antibodies, Monoclonal - adverse effects | Liver Neoplasms - drug therapy | Male | Response Evaluation Criteria in Solid Tumors | Treatment Outcome | Antineoplastic Agents - administration & dosage | Tumor Burden | Dose-Response Relationship, Drug | B7-H1 Antigen - metabolism | Carcinoma, Hepatocellular - drug therapy | Time Factors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Nivolumab | Carcinoma, Hepatocellular - pathology | Biomarkers, Tumor - metabolism | Female | Liver Neoplasms - pathology | Aged | Virus diseases | Medical colleges | Care and treatment | Cell death | College teachers | Hepatoma | Comparative analysis | Drug approval | Slopes | Therapy | Pemphigoid | Intravenous administration | Inhibitor drugs | PD-1 protein | Funding | Liver | Medical services | Clinical trials | Hepatocellular carcinoma | Lymphocytes T | Infections | Metastasis | Dosage | Cancer therapies | B7 antigen | Acceptability | Incidence | Hepatitis | Liver cancer | Pathways | Quality | Immunotherapy | Safety engineering | Safety management | Safety | Expansion | Drug dosages | Liver diseases | Effectiveness | Mortality | Group dynamics | Patients | Hospitals | Inhibitors | Immune checkpoint | Adults | Solid tumors | Hepatitis C virus | Hepatitis C | Tumors | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2016, Volume 22, Issue 24, pp. 6300 - 6300
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1893 - 1901
Summary Background Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We aimed to assess its safety and tolerability and to establish... 
Internal Medicine | SURVIVAL | IRRADIATION | MEDICINE, GENERAL & INTERNAL | PATHWAY | RAF INHIBITOR RESISTANCE | B-RAF | MUTATIONS | CANCER | BRAF(V600E) | VEMURAFENIB | Oximes - adverse effects | Humans | Middle Aged | Carcinoma, Squamous Cell - chemically induced | Oximes - administration & dosage | Imidazoles - administration & dosage | Male | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Fever - chemically induced | Indoles - administration & dosage | Brain Neoplasms - secondary | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Melanoma - genetics | Adult | Female | Drug Administration Schedule | Imidazoles - adverse effects | Genotype | Treatment Outcome | Skin Neoplasms - chemically induced | Brain Neoplasms - drug therapy | Mutation - genetics | Melanoma - secondary | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Maximum Tolerated Dose | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Complications and side effects | Melanoma | Dosage and administration | Metastasis | Antineoplastic agents | Drug therapy | Clinical trials | Medical research | Chemotherapy | Mutation | Toxicity | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2017, Volume 18, Issue 11, pp. 1512 - 1522
Antibody–drug conjugates have emerged as a powerful strategy in cancer therapy and combine the ability of monoclonal antibodies to specifically target tumour... 
HETEROGENEITY | EMTANSINE | THERAPY | ONCOLOGY | CANCER AMERICAN SOCIETY | CLINICAL-PRACTICE GUIDELINE | GENE AMPLIFICATION | JUNCTION CANCER | HER2 STATUS | OPEN-LABEL | PLUS PACLITAXEL | Breast Neoplasms - surgery | Prognosis | Receptor, ErbB-2 - genetics | Trastuzumab - pharmacokinetics | Humans | Middle Aged | Mastectomy - methods | Male | Stomach Neoplasms - pathology | Esophageal Neoplasms - pathology | Dose-Response Relationship, Drug | Neoplasm Invasiveness - pathology | Patient Safety | Esophageal Neoplasms - mortality | Immunoconjugates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Receptor, ErbB-2 - drug effects | Stomach Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Trastuzumab - therapeutic use | Drug Administration Schedule | Japan | Kaplan-Meier Estimate | Trastuzumab - adverse effects | Treatment Outcome | Stomach Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - genetics | Esophageal Neoplasms - genetics | Survival Analysis | Breast Neoplasms - mortality | Aged | Neoplasm Staging | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Antimitotic agents | Care and treatment | Safety and security measures | Monoclonal antibodies | Antineoplastic agents | Biopharmaceutics | Tumors | Enzymes | Medical research | Analysis | Medicine, Experimental | Health aspects | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 08/2017, Volume 123, Issue 16, pp. 3080 - 3087
Mirvetuximab soravtansine (IMGN853) is an antibody‐drug conjugate that targets folate receptor α for tumor‐directed delivery of the maytansinoid DM4, a potent... 
clinical trial | targeted therapy | folate receptor | phase 1 | antibody‐drug conjugate | antibody-drug conjugate | THERAPEUTICS | FARLETUZUMAB | PLATINUM-RESISTANT OVARIAN | MONOCLONAL-ANTIBODY | COMBINATION | EPITHELIAL OVARIAN-CANCER | CHEMOTHERAPY | DELIVERY | THERAPY | ONCOLOGY | PROTEINS | Lung Neoplasms - drug therapy | Humans | Middle Aged | Ovarian Neoplasms - pathology | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Vision Disorders - chemically induced | Aged, 80 and over | Immunoconjugates - therapeutic use | Adult | Female | Hypophosphatemia - chemically induced | Carcinoma, Renal Cell - drug therapy | Ovarian Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - pathology | Neoplasms, Glandular and Epithelial - pathology | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma, Renal Cell - pathology | Maytansine - analogs & derivatives | Keratitis - chemically induced | Maytansine - therapeutic use | Disease Progression | Neoplasms - drug therapy | Maximum Tolerated Dose | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Kidney Neoplasms - pathology | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Kidney Neoplasms - drug therapy | Neoplasms - pathology | Cancer patients | Care and treatment | Pharmacokinetics | Health aspects | Analysis | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article